You are here: Scientific Programme > 
DeutschEnglishFrancais
1/28/2012 : 12:39 am



Programme Overview

The scientific program covers the whole spectrum of nuclear medicine. Besides scientific sessions with proffered papers - these will be presented either orally or as posters - several special events are scheduled to discuss topics of interest. 

The Gastein Lecture

Chair: P.A. Schubiger (Zurich)

  • W. Weber (Freiburg):
    PET/CT as tool for personalized therapy

The European Corner

Standardization of PET data: Intercomparison of images

  • A. Bockisch (Essen):
    Clinical aspects - a physician's view
  • R. Boellaard (Amsterdam):
    Physical aspects - a physicist's view

Distinguished Pioneer´s Lecture

Chair: R. Höfer (Vienna)

  • H. Mäcke (Freiburg):
    Agonists or antagonists for peptide-based tumour imaging and radionuclide therapy?

Fireside Conference

  • K.J. Langen (Juelich):
    PET in neuro-oncology
  • B. Pichler (Tuebingen):
    PET/MRI and the brain
  • K. Fraps (Munich):
    PET: The magic of new concepts

Radionuclide Therapy

  • H.J. Biersack (Bonn):
    Selective Internal Radiation Therapy (SIRT) of liver malignancies
  • D.J. Kwekkeboom (Rotterdam):
    How far are we from evidence in radiopeptide therapy?

Neurology/Psychiatry

  • P. Dal Bianco (Vienna):
    Dementias of old age
  • K. Herholz (Manchester):
    Current developments in the imaging of dementia
  • S. Kasper (Vienna):
    A beautiful mind - PET in psychiatry

Cardiology

  • H. Schelbert (Los Angeles):
    From microvessels to metabolism and remodelling
  • P.A. Kaufmann (Zurich)
    New trends in myocardial perfusion imaging

Oncology

  • J. Czernin (Los Angeles):
    The cost (effectiveness) of cancer imaging
  • R. Wahl (Baltimore):
    PERCIST: A new look at tumour response

MERCK Lunch Symposium

  • M. Weissel (Vienna):
    Thyroid and pregnancy
  • M. Raderer (Vienna):
    New therapeutic trends in radioiodine-negative thyroid cancer patients

Radiopharmaceutical Sciences:

  • S. Ametamey (Zurich):
    PET radioligands for the glutamatergic system
  • H.H. Coenen (Juelich):
    Benefits of PET-radiotracers for drug development
  • J. Steinbach (Dresden-Rossendorf):
    Radiotracers for the cholinergic system

The Physicist's Corner

  • M. Sámal (Prague):
    Current concepts of quantitative renal imaging
  • A.E. Todd-Pokropek (London):
    The place of 'quantitative' nuclear medicine in the administration of therapy

The Industry Corner

PET/MR as Low Dose PET/CT?

Nach oben